Oppenheimer Asset Management Inc. increased its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 7.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 258,140 shares of the pharmaceutical company’s stock after purchasing an additional 17,043 shares during the period. Oppenheimer Asset Management Inc.’s holdings in GlaxoSmithKline were worth $10,480,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GSK. Renaissance Technologies LLC increased its position in shares of GlaxoSmithKline by 112.1% during the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after purchasing an additional 4,935,900 shares during the period. FMR LLC increased its position in shares of GlaxoSmithKline by 5.9% during the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after purchasing an additional 1,389,238 shares during the period. Federated Investors Inc. PA increased its position in shares of GlaxoSmithKline by 22.7% during the second quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock valued at $194,521,000 after purchasing an additional 833,501 shares during the period. Marshall Wace North America L.P. increased its position in shares of GlaxoSmithKline by 148.0% during the second quarter. Marshall Wace North America L.P. now owns 1,119,491 shares of the pharmaceutical company’s stock valued at $48,138,000 after purchasing an additional 668,088 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC boosted its stake in GlaxoSmithKline by 7.3% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock valued at $341,727,000 after buying an additional 569,600 shares in the last quarter. Institutional investors and hedge funds own 9.83% of the company’s stock.

GlaxoSmithKline plc (NYSE GSK) traded down $0.20 during trading on Thursday, reaching $34.66. The company’s stock had a trading volume of 5,771,900 shares, compared to its average volume of 3,507,768. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. The firm has a market capitalization of $85,732.63, a price-to-earnings ratio of 12.36, a P/E/G ratio of 1.93 and a beta of 0.98. GlaxoSmithKline plc has a one year low of $34.52 and a one year high of $44.53.

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be paid a dividend of $0.5037 per share. This represents a $2.01 annualized dividend and a dividend yield of 5.81%. The ex-dividend date of this dividend is Thursday, November 9th. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio is 163.12%.

In other news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were acquired at an average price of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.00% of the company’s stock.

Several analysts recently commented on GSK shares. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Wednesday, October 18th. Morgan Stanley lowered GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. Argus reissued a “buy” rating and issued a $50.00 price objective on shares of GlaxoSmithKline in a research note on Thursday, August 31st. TheStreet raised GlaxoSmithKline from a “c+” rating to a “b” rating in a research note on Wednesday, October 25th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, October 24th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus target price of $39.71.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/12/07/glaxosmithkline-plc-gsk-holdings-lifted-by-oppenheimer-asset-management-inc.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.